Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs
Article first published online: 6 DEC 2006
Journal of Small Animal Practice
Volume 48, Issue 3, pages 139–144, March 2007
How to Cite
Passmore, C. A., Sherington, J. and Stegemann, M. R. (2007), Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs. Journal of Small Animal Practice, 48: 139–144. doi: 10.1111/j.1748-5827.2006.00231.x
- Issue published online: 6 DEC 2006
- Article first published online: 6 DEC 2006
Objectives: To determine the efficacy and safety of cefovecin (ConveniaTM; Pfizer Animal Health) in the treatment of urinary tract infections in dogs.
Methods: A multi-centre, blinded, randomised study was conducted in 129 dogs with urinary tract infections. Cephalexin (RilexineTM) administered twice daily at 15 mg/kg bodyweight orally for 14 days was compared with a single, subcutaneous injection of cefovecin (ConveniaTM) in dogs. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.
Results: One hundred and twenty-nine dogs were included in efficacy assessments. Escherichia coli was eliminated in 90·5 per cent of cefovecin-treated dogs compared with 52·9 per cent of cephalexin-treated dogs (P=0·0004). Overall cure rates for dogs with Escherichia coli infections were 79·1 per cent for cefovecin and 36·4 per cent for cephalexin-treated dogs (P=0·0003). There were no suspected adverse drug reactions attributed to treatment with cefovecin or cephalexin.
Clinical Significance: Cefovecin was shown to be an effective and safe treatment for urinary tract infections.